4.7 Article

αvβ3 and αvβ5 integrins control glioma cell response to ionising radiation through ILK and RhoB

期刊

INTERNATIONAL JOURNAL OF CANCER
卷 123, 期 2, 页码 357-364

出版社

WILEY
DOI: 10.1002/ijc.23498

关键词

glioblastoma; radiosensitivity; integrin; ILK; RhoB

类别

向作者/读者索取更多资源

Integrins are extracellular matrix receptors involved in tumour invasion and angiogenesis. Although there is evidence that inhibiting integrins might enhance the efficiency of radiotherapy, little is known about the exact mechanisms involved in the integrin-dependent modulation of tumor radiosensitivity. The purpose of this study was to investigate the role of alpha v beta 3 and alpha v beta 5 integrins in glioblastoma cell radioresistance and overall to decipher the downstream biological pathways. We first demonstrated that silencing alpha v beta 3 and alpha v beta 5 integrins with specific siRNAs significantly reduced the survival after irradiation of 2 glioblastoma cell lines: U87 and SF763. We then showed that integrin activity and integrin signalling pathways controlled the glioma cell radiosensitivity. This regulation of glioma cell response to ionising radiation was mediated through the integrin-linked kinase, ILK, and the small GTPase, RhoB, by two mechanisms. The first one, independent of ILK, consists in the regulation of the intracellular level of RhoB by alpha v beta 3 or alpha v beta 5 integrin. The second pathway involved in cell radiosensitivity consists in RhoB activation by ionising radiation through ILK. Furthermore, we demonstratead that the alpha v beta 3/alpha v beta 5 integrins/ILK/ RhoB pathway controlled the glioma cells radiosensitivity by regulating radiation-induced mitotic cell death. This work identifies a new biological pathway controlling glioblastoma cells radioresistance, activated from the membrane through alpha v beta 3 and/or alpha v beta 5 integrins via ILK and RhoB. Our results are clues that downstream effectors of alpha v beta 3 and alpha v beta 5 integrins as ILK and RhoB might also be promising candidate targets for improving the efficiency of radiotherapy and thus the clinical outcome of patients with glioblastoma. (C) 2008 Wiley-Liss, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据